Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05438160 · ClinicalTrials.gov registry record · NA
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
A NA study of Schizophrenia, sponsored by Click Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 7
- Study locations
NCT05438160: Completed NA study of Schizophrenia, sponsored by Click Therapeutics.
NCT05438160 is a NA study of Schizophrenia that has completed, run by Click Therapeutics. The registered enrollment target is 48 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05438160, a NA study of Schizophrenia, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 7
- Study locations
Study Summary
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
Primary Outcome
Degree of participant engagement with the study app as measured by participant app use data captured in-app
Conditions Studied
Interventions
- DEVICE Clinical Learning Study smartphone app (i.e., the study app)
Study Locations (7)
Florida
- CT-155 Center - Hialeah
- CT-155 Center - Lake Mary
- CT-155 Center - Miami
California
- CT-155 Center - Anaheim
- CT-155 Center - Torrance
Texas
- CT-155 Center - Irving
- CT-155 Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2022-07-31 |
| Phase | NA |
What the finished NCT05438160 record still lists
NCT05438160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Clinical Learning Study smartphone app (i.e., the study app) is the first listed.
NCT05438160 lists 7 locations in 3 states (Florida, California, Texas).
Frequently Asked Questions
What is clinical trial NCT05438160 about?
NCT05438160 is a clinical study titled "Exploratory Study of a Digital Therapeutics in People With Schizophrenia". CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
What is the current status of trial NCT05438160?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2022-03-31. Estimated completion is 2022-07-31.
What conditions does trial NCT05438160 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT05438160?
The interventions under investigation include: Clinical Learning Study smartphone app (i.e., the study app) (DEVICE).
Who is sponsoring clinical trial NCT05438160?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05438160 being conducted?
This trial has 7 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05438160's enrollment target sits among peer trials
48 218th of 315 higher than 94 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI